Discovery Labs has reorganised its executive management, appointing Thomas Miller as chief operating officer, Charles Katzer as chief technical officer and John Cooper as president and chief financial officer.
Katzer, who will assume responsibility for manufacturing, has previously worked at MedImmune and Baxter. Miller has previously worked at firms including Pfizer, Novartis, BASF Pharmaceuticals and Johnson & Johnson, and Cooper has held positions at ENI Diagnostics.
Christopher Begley is to step down as CEO of Hospira after six years in the position. Begley will continue as CEO until Hospira has named his successor. After stepping down Begley will continue at Hospira as executive chairman of the board of directors.
Frank Baldino, CEO of Cephalon, has taken temporary medical leave. Kevin Buchi, chief operating officer at Cephalon, will assume his responsibilities. Buchi has worked at Cephalon for almost 20 years.
Biopharm tubing manufacturer NewAge Industries has named Bill Keiser as director of quality. Keiser worked as an independent consultant for NewAge before joining the company full-time.
Lara Longpre has joined Jennerex as chief operating officer. Longpre has 17 years of clinical research experience at companies including MedGenesis Therapeutix and PRA International.
Iroko Cardio International has appointed Jürgen Raths as CEO. Iroko is a newly created business focused on the commercialisation of Aggrastat (tirofiban) outside the US.
Larry Kranking has been named as president and CEO of Coldstream Laboratories. Kranking has held a number of manufacturing and quality roles at companies including Pharmaceutical Intergrators, Eisai, ISPE and Boehringer Ingelheim.
PPD has appointed Neil McCullough as vice president of quality management systems. McCullough worked for nine years at Pfizer and served as a consultant to GlaxoSmithKline’s division of manufacturing.